Understanding the FIB-4 Index (Fibrosis-4 Score)
The FIB-4 (Fibrosis-4) index is a validated, noninvasive score used to estimate the likelihood of advanced liver fibrosis (scarring) from routine blood work. It was derived by Sterling and colleagues (2006) in patients with chronic hepatitis C/HIV co-infection and has since been widely adopted for chronic hepatitis B and non-alcoholic fatty liver disease (NAFLD/NASH) as a first-line, low-cost triage tool that helps decide who may need further testing, such as elastography (FibroScan) or a liver biopsy, and who can be safely monitored in primary care.
How the FIB-4 score is calculated
FIB-4 combines four routinely available values into one formula: FIB-4 = (Age × AST) ÷ (Platelet count × √ALT). Age is in years; AST (aspartate aminotransferase) and ALT (alanine aminotransferase) are liver enzyme levels in U/L from a standard liver panel; and platelet count is entered in ×10⁹/L — the same number your lab report shows (for example, enter 200, not 200,000). A higher AST relative to ALT and platelets, combined with older age, pushes the score up, which is consistent with the biological picture of advancing fibrosis: enzyme patterns shift and platelet counts fall as portal hypertension develops.
Interpreting your FIB-4 result
Using the original Sterling et al. thresholds: a score below 1.45 indicates a low probability of advanced fibrosis (F3-F4) and generally rules out significant scarring; a score above 3.25 indicates a high probability of advanced fibrosis and typically warrants hepatology referral; and scores in the 1.45-3.25 indeterminate zone are inconclusive and usually call for a second-line test such as transient elastography or specialist assessment. Some NAFLD-specific guidelines use tighter cutoffs (roughly 1.30 and 2.67) to optimize sensitivity in that population — your clinician will know which threshold applies to your situation.
Limitations and when to see a specialist
FIB-4 is a screening estimate, not a diagnosis. It can be less reliable at the extremes of age — it tends to overestimate fibrosis risk in people over 65 and underestimate it in those under 35 — and it was not designed for patients with acute hepatitis, other causes of thrombocytopenia, or advanced kidney disease. Always discuss an indeterminate or high result with a physician or hepatologist; this calculator is for education only and is not a substitute for professional medical advice, diagnosis, or treatment.